Boothbay Fund Management LLC Trims Stock Position in Evolus, Inc. $EOLS

Key Points

• Boothbay Fund Management LLC has reduced its stake in Evolus, Inc. by 11.4%, now holding approximately $13.73 million in the company's stock after selling over 146,000 shares.
• The company has a market capitalization of $477.34 million and is currently trading at $7.38, with a one-year price range between $5.71 and $17.82.
• Recent analyst ratings show a consensus of "Moderate Buy" for Evolus, with price targets varying from $18.00 to $22.00 based on recent reports.

Boothbay Fund Management LLC trimmed its stake in shares of Evolus, Inc. (NASDAQ:EOLS - Free Report) by 11.4% in the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 1,141,224 shares of the company's stock after selling 146,543 shares during the quarter. Boothbay Fund Management LLC owned 1.77% of Evolus worth $13,729,000 at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently bought and sold shares of EOLS. Raymond James Financial Inc. acquired a new position in Evolus during the 4th quarter worth $575,000. MetLife Investment Management LLC grew its stake in Evolus by 6.3% during the 4th quarter. MetLife Investment Management LLC now owns 34,272 shares of the company's stock worth $378,000 after purchasing an additional 2,044 shares in the last quarter. Price T Rowe Associates Inc. MD grew its stake in Evolus by 13.7% during the 4th quarter. Price T Rowe Associates Inc. MD now owns 52,593 shares of the company's stock worth $581,000 after purchasing an additional 6,332 shares in the last quarter. Northern Trust Corp grew its stake in Evolus by 9.3% during the 4th quarter. Northern Trust Corp now owns 531,167 shares of the company's stock worth $5,864,000 after purchasing an additional 45,384 shares in the last quarter. Finally, Schonfeld Strategic Advisors LLC grew its stake in Evolus by 62.6% during the 4th quarter. Schonfeld Strategic Advisors LLC now owns 34,700 shares of the company's stock worth $383,000 after purchasing an additional 13,363 shares in the last quarter. 90.69% of the stock is owned by institutional investors and hedge funds.

Insider Transactions at Evolus

In other news, Director Brady Stewart bought 30,000 shares of Evolus stock in a transaction dated Friday, August 15th. The stock was acquired at an average cost of $6.82 per share, with a total value of $204,600.00. Following the acquisition, the director owned 88,629 shares of the company's stock, valued at approximately $604,449.78. This trade represents a 51.17% increase in their ownership of the stock. The acquisition was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CMO Tomoko Yamagishi-Dressler sold 5,722 shares of the business's stock in a transaction dated Friday, August 22nd. The shares were sold at an average price of $7.51, for a total value of $42,972.22. Following the completion of the sale, the chief marketing officer directly owned 89,949 shares of the company's stock, valued at $675,516.99. The trade was a 5.98% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders sold a total of 133,627 shares of company stock valued at $1,325,764 over the last quarter. Company insiders own 5.90% of the company's stock.

Evolus Stock Performance

Shares of Evolus stock traded up $0.15 on Friday, hitting $7.66. The stock had a trading volume of 534,857 shares, compared to its average volume of 1,155,379. Evolus, Inc. has a 52-week low of $5.71 and a 52-week high of $17.82. The company has a current ratio of 2.27, a quick ratio of 1.86 and a debt-to-equity ratio of 22.00. The stock has a market cap of $495.45 million, a price-to-earnings ratio of -7.82 and a beta of 1.07. The company's 50 day moving average price is $8.26 and its 200 day moving average price is $10.16.

Analyst Upgrades and Downgrades

Several research analysts recently commented on EOLS shares. BTIG Research lowered their target price on Evolus from $21.00 to $18.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Needham & Company LLC reissued a "hold" rating and set a $22.00 target price on shares of Evolus in a research note on Wednesday, August 6th. HC Wainwright lowered their target price on Evolus from $27.00 to $20.00 and set a "buy" rating for the company in a research note on Wednesday, August 6th. Finally, Wall Street Zen downgraded Evolus from a "hold" rating to a "sell" rating in a report on Saturday, August 9th. Four equities research analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company. According to MarketBeat.com, Evolus currently has an average rating of "Moderate Buy" and an average target price of $21.25.

About Evolus

Evolus, Inc, a performance beauty company, focuses on delivering products in the cash-pay aesthetic market in the United States, Canada, and Europe. The company offers Jeuveau, a proprietary 900 kilodalton purified botulinum toxin type A formulation for the temporary improvement in the appearance of moderate to severe glabellar lines in adults.